keyword
MENU ▼
Read by QxMD icon Read
search

David Nutt

keyword
https://www.readbyqxmd.com/read/28631527/buprenorphine-naloxone-versus-methadone-and-lofexidine-in-community-stabilisation-and-detoxification-a-randomised-controlled-trial-of-low-dose-short-term-opiate-dependent-individuals
#1
Fergus D Law, Alison M Diaper, Jan K Melichar, Simon Coulton, David J Nutt, Judy S Myles
Buprenorphine/naloxone, methadone and lofexidine are medications with utility in the treatment of opiate withdrawal. We report the first randomised controlled trial to compare the effects of these two medications on withdrawal symptoms and outcome during opiate induction/stabilisation and detoxification. A double-blind randomised controlled trial was conducted in an outpatient satellite clinic of a specialist drug service. Eighty opiate dependent individuals meeting DSM-IV criteria for opiate dependence, using ⩽ ½ g heroin smoked/chased or ¼ g heroin injected or ⩽ 30mg methadone, with ⩽ 3 years of opioid dependency, underwent a short-term opiate treatment programme involving induction/stabilisation on methadone 30mg or buprenorphine/naloxone 4mg/1mg, followed by detoxification (where the methadone group was assisted by lofexidine)...
June 1, 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28531767/the-standard-joint-unit
#2
Cristina Casajuana Kögel, María Mercedes Balcells-Olivero, Hugo López-Pelayo, Laia Miquel, Lídia Teixidó, Joan Colom, David John Nutt, Jürgen Rehm, Antoni Gual
OBJECTIVE: Reliable data on cannabis quantities is required to improve assessment of cannabis consumption for epidemiological analysis and clinical assessment, consequently a Standard Joint Unit (SJU) based on quantity of 9-Tetrahydrocannabinol (9-THC) has been established. METHODOLOGY: Naturalistic study of a convenience sample recruited from February 2015-June 2016 in universities, leisure spaces, mental health services and cannabis clubs in Barcelona. Adults, reporting cannabis use in the last 60 days, without cognitive impairment or language barriers, answered a questionnaire on cannabis use and were asked to donate a joint to further determine their 9-THC and Cannabidiol (CBD) content...
May 16, 2017: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/28496172/acute-d3-antagonist-gsk598809-selectively-enhances-neural-response-during-monetary-reward-anticipation-in-drug-and-alcohol-dependence
#3
Anna Murphy, Liam J Nestor, John McGonigle, Louise Paterson, Venkataramana Boyapati, Karen D Ersche, Remy Flechais, Shankar Kuchibatla, Antonio Metastasio, Csaba Orban, Filippo Passetti, Laurence Reed, Dana Smith, John Suckling, Eleanor Taylor, Trevor Wr Obbins, Anne Lingford-Hughes, David J Nutt, John Fw Deakin, Rebecca Elliott
No abstract text is available yet for this article.
June 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28395988/ketamine-treatment-for-depression-opportunities-for-clinical-innovation-and-ethical-foresight
#4
REVIEW
Ilina Singh, Celia Morgan, Valerie Curran, David Nutt, Anne Schlag, Rupert McShane
We present a review and analysis of the ethical considerations in off-label ketamine use for severe, treatment-resistant depression. The analysis of ethical considerations is contextualised in an overview of the evidence for ketamine use in depression, and a review of the drug's safety profile. We find that, based on current evidence, ketamine use for severe, treatment-resistant depression does not violate ethical principles; however, clinicians and professional bodies must take steps to ensure that guidelines for good practice are enacted, that all experimental and trial data are made available through national registries, and that the risk potential of ketamine treatment continues to be monitored and modelled...
May 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/28382966/the-pu-1-target-gene-zbtb11-regulates-neutrophil-development-through-its-integrase-like-hhcc-zinc-finger
#5
Maria-Cristina Keightley, Duncan P Carradice, Judith E Layton, Luke Pase, Julien Y Bertrand, Johannes G Wittig, Aleksandar Dakic, Andrew P Badrock, Nicholas J Cole, David Traver, Stephen L Nutt, Julia McCoey, Ashley M Buckle, Joan K Heath, Graham J Lieschke
In response to infection and injury, the neutrophil population rapidly expands and then quickly re-establishes the basal state when inflammation resolves. The exact pathways governing neutrophil/macrophage lineage outputs from a common granulocyte-macrophage progenitor are still not completely understood. From a forward genetic screen in zebrafish, we identify the transcriptional repressor, ZBTB11, as critical for basal and emergency granulopoiesis. ZBTB11 sits in a pathway directly downstream of master myeloid regulators including PU...
April 6, 2017: Nature Communications
https://www.readbyqxmd.com/read/28247526/naltrexone-ameliorates-functional-network-abnormalities-in-alcohol-dependent-individuals
#6
Laurel S Morris, Kwangyeol Baek, Roger Tait, Rebecca Elliott, Karen D Ersche, Remy Flechais, John McGonigle, Anna Murphy, Liam J Nestor, Csaba Orban, Filippo Passetti, Louise M Paterson, Ilan Rabiner, Laurence Reed, Dana Smith, John Suckling, Eleanor M Taylor, Edward T Bullmore, Anne R Lingford-Hughes, Bill Deakin, David J Nutt, Barbara J Sahakian, Trevor W Robbins, Valerie Voon
Naltrexone, an opioid receptor antagonist, is commonly used as a relapse prevention medication in alcohol and opiate addiction, but its efficacy and the mechanisms underpinning its clinical usefulness are not well characterized. In the current study, we examined the effects of 50-mg naltrexone compared with placebo on neural network changes associated with substance dependence in 21 alcohol and 36 poly-drug-dependent individuals compared with 36 healthy volunteers. Graph theoretic and network-based statistical analysis of resting-state functional magnetic resonance imaging (MRI) data revealed that alcohol-dependent subjects had reduced functional connectivity of a dispersed network compared with both poly-drug-dependent and healthy subjects...
February 28, 2017: Addiction Biology
https://www.readbyqxmd.com/read/28224686/addiction-research-and-theory-a-commentary-on-the-surgeon-general-s-report-on-alcohol-drugs-and-health
#7
Aldo Badiani, Kent C Berridge, Markus Heilig, David J Nutt, Terry E Robinson
The Office of the Surgeon General recently produced its first Report on the consequences of alcohol and drug abuse on health, making several very laudable policy recommendations. The Report also emphasizes the importance of adequate funding for biomedical research, which is good news for both researchers and patients. However, the Report is marred by a biased viewpoint on the psychology and neurobiology of drug addiction. We highlight here four controversial issues that were depicted as facts in the Report, thereby potentially misleading non-expert readers about the current state-of-the-art understanding of the psychology and neurobiology of drug addiction...
February 21, 2017: Addiction Biology
https://www.readbyqxmd.com/read/28216062/nalmefene-reduces-reward-anticipation-in-alcohol-dependence-an-experimental-functional-magnetic-resonance-imaging-study
#8
Darren R Quelch, Inge Mick, John McGonigle, Anna C Ramos, Remy S A Flechais, Mark Bolstridge, Eugenii Rabiner, Matthew B Wall, Rexford D Newbould, Björn Steiniger-Brach, Franz van den Berg, Malcolm Boyce, Dorrit Østergaard Nilausen, Lasse Breuning Sluth, Didier Meulien, Christoph von der Goltz, David Nutt, Anne Lingford-Hughes
BACKGROUND: Nalmefene is a µ and δ opioid receptor antagonist, κ opioid receptor partial agonist that has recently been approved in Europe for treating alcohol dependence. It offers a treatment approach for alcohol-dependent individuals with "high-risk drinking levels" to reduce their alcohol consumption. However, the neurobiological mechanism underpinning its effects on alcohol consumption remains to be determined. Using a randomized, double-blind, placebo-controlled, within-subject crossover design we aimed to determine the effect of a single dose of nalmefene on striatal blood oxygen level-dependent (BOLD) signal change during anticipation of monetary reward using the monetary incentive delay task following alcohol challenge...
June 1, 2017: Biological Psychiatry
https://www.readbyqxmd.com/read/28195139/altered-insula-connectivity-under-mdma
#9
Ishan C Walpola, Timothy Nest, Leor Roseman, David Erritzoe, Amanda Feilding, David J Nutt, Robin L Carhart-Harris
Recent work with noninvasive human brain imaging has started to investigate the effects of 3, 4-methylenedioxymethamphetamine (MDMA) on large-scale patterns of brain activity. MDMA, a potent monoamine-releaser with particularly pronounced serotonin- releasing properties, has unique subjective effects that include: marked positive mood, pleasant/unusual bodily sensations and pro-social, empathic feelings. However, the neurobiological basis for these effects is not properly understood, and the present analysis sought to address this knowledge gap...
February 14, 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28167221/toxicological-evaluation-of-5-methoxy-2-aminoindane-meai-binge-mitigating-agent-in-development
#10
Jakob A Shimshoni, Ilan Winkler, Nir Edery, Ezekiel Golan, René van Wettum, David Nutt
5-Methoxy-2-aminoindane (MEAI) is a psychoactive compound of the aminoindane class, which in recent years has been recreationally used by many people, who reported of a mild euphoric, alcohol-like tipsy experience and reduced desire to consume alcoholic beverages. In the light of these observations it was decided to progress MEAI through a preliminary drug development route and evaluate the acute and subacute toxicity of MEAI administrated orally to Sprague Dawley rats, as well as to determine potential in-vitro cytotoxic and mutagenic effects using state-of-the-art protocols...
March 15, 2017: Toxicology and Applied Pharmacology
https://www.readbyqxmd.com/read/28092199/book-reviewsreviews
#11
Márta Virág, Kollár Tamás
Michael S. Gazzaniga, Richard B. Ivry and George R. Mangun Cognitive neuroscience: The biology of the mind (International student edition) (4th ed.) Trevor W. Robbins, Barry J. Everitt and David J. Nutt The neurobiology of addiction Oxford, UK: Oxford University Press, 2010, 318 pp. ISBN: 978-0-1995-6215-2.
March 2016: Journal of Behavioral Addictions
https://www.readbyqxmd.com/read/28042871/acute-d3-antagonist-gsk598809-selectively-enhances-neural-response-during-monetary-reward-anticipation-in-drug-and-alcohol-dependence
#12
Anna Murphy, Liam J Nestor, John McGonigle, Louise Paterson, Venkataramana Boyapati, Karen D Ersche, Remy Flechais, Shankar Kuchibatla, Antonio Metastasio, Csaba Orban, Filippo Passetti, Laurence Reed, Dana Smith, John Suckling, Eleanor Taylor, Trevor W Robbins, Anne Lingford-Hughes, David J Nutt, John Fw Deakin, Rebecca Elliott
Evidence suggests that disturbances in neurobiological mechanisms of reward and inhibitory control maintain addiction and provoke relapse during abstinence. Abnormalities within the dopamine system may contribute to these disturbances and pharmacologically targeting the D3 dopamine receptor (DRD3) is therefore of significant clinical interest. We used functional magnetic resonance imaging to investigate the acute effects of the DRD3 antagonist GSK598809 on anticipatory reward processing, using the monetary incentive delay task (MIDT), and response inhibition using the Go/No-Go task (GNGT)...
April 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27955830/inverse-agonists-what-do-they-mean-for-psychiatry
#13
David Nutt, Stephen Stahl, Pierre Blier, Filippo Drago, Joseph Zohar, Sue Wilson
The nomenclature of drugs is a critical aspect of science, since it can direct research and optimize treatment choices. Traditionally drugs acting on CNS receptors have been classified as either agonists or antagonists. Recently a new class of ligand, the inverse agonist, has been identified in some receptor systems. Inverse agonists have opposite actions to those of agonists but the effects of both of these can be blocked by antagonists. Pimavanserin is a new 5-HT2A receptor acting drug that has been given market authorization for psychosis in Parkinson׳s disease...
January 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27909163/psilocybin-for-anxiety-and-depression-in-cancer-care-lessons-from-the-past-and-prospects-for-the-future
#14
EDITORIAL
David Nutt
No abstract text is available yet for this article.
December 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27834755/thirty-years-of-journal-of-psychopharmacology
#15
EDITORIAL
David J Nutt
No abstract text is available yet for this article.
November 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27739164/evidence-for-gaba-a-receptor-dysregulation-in-gambling-disorder-correlation-with-impulsivity
#16
Inge Mick, Anna C Ramos, Jim Myers, Paul R Stokes, Samantha Chandrasekera, David Erritzoe, Maria A Mendez, Roger N Gunn, Eugenii A Rabiner, Graham E Searle, José C F Galduróz, Adam D Waldman, Henrietta Bowden-Jones, Luke Clark, David J Nutt, Anne R Lingford-Hughes
As a behavioural addiction, gambling disorder (GD) provides an opportunity to characterize addictive processes without the potentially confounding effects of chronic excessive drug and alcohol exposure. Impulsivity is an established precursor to such addictive behaviours, and GD is associated with greater impulsivity. There is also evidence of GABAergic dysregulation in substance addiction and in impulsivity. This study therefore investigated GABAA receptor availability in 15 individuals with GD and 19 healthy volunteers (HV) using [(11) C]Ro15-4513, a relatively selective α5 benzodiazepine receptor PET tracer and its relationship with impulsivity...
October 13, 2016: Addiction Biology
https://www.readbyqxmd.com/read/27705084/levosimendan-for-the-prevention-of-acute-organ-dysfunction-in-sepsis
#17
Anthony C Gordon, Gavin D Perkins, Mervyn Singer, Daniel F McAuley, Robert M L Orme, Shalini Santhakumaran, Alexina J Mason, Mary Cross, Farah Al-Beidh, Janis Best-Lane, David Brealey, Christopher L Nutt, James J McNamee, Henrik Reschreiter, Andrew Breen, Kathleen D Liu, Deborah Ashby
BACKGROUND: Levosimendan is a calcium-sensitizing drug with inotropic and other properties that may improve outcomes in patients with sepsis. METHODS: We conducted a double-blind, randomized clinical trial to investigate whether levosimendan reduces the severity of organ dysfunction in adults with sepsis. Patients were randomly assigned to receive a blinded infusion of levosimendan (at a dose of 0.05 to 0.2 μg per kilogram of body weight per minute) for 24 hours or placebo in addition to standard care...
October 27, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27703042/the-iccam-platform-study-an-experimental-medicine-platform-for-evaluating-new-drugs-for-relapse-prevention-in-addiction-part-b-fmri-description
#18
John McGonigle, Anna Murphy, Louise M Paterson, Laurence J Reed, Liam Nestor, Jonathan Nash, Rebecca Elliott, Karen D Ersche, Remy Sa Flechais, Rexford Newbould, Csaba Orban, Dana G Smith, Eleanor M Taylor, Adam D Waldman, Trevor W Robbins, Jf William Deakin, David J Nutt, Anne R Lingford-Hughes, John Suckling
OBJECTIVES: We aimed to set up a robust multi-centre clinical fMRI and neuropsychological platform to investigate the neuropharmacology of brain processes relevant to addiction - reward, impulsivity and emotional reactivity. Here we provide an overview of the fMRI battery, carried out across three centres, characterizing neuronal response to the tasks, along with exploring inter-centre differences in healthy participants. EXPERIMENTAL DESIGN: Three fMRI tasks were used: monetary incentive delay to probe reward sensitivity, go/no-go to probe impulsivity and an evocative images task to probe emotional reactivity...
January 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27688219/strengthening-health-systems-while-responding-to-a-health-crisis-lessons-learned-by-a-nongovernmental-organization-during-the-ebola-virus-disease-epidemic-in-sierra-leone
#19
Corrado Cancedda, Sheila M Davis, Kerry L Dierberg, Jonathan Lascher, J Daniel Kelly, Mohammed Bailor Barrie, Alimamy Philip Koroma, Peter George, Adikali Alpha Kamara, Ronald Marsh, Manso S Sumbuya, Cameron T Nutt, Kirstin W Scott, Edgar Thomas, Katherine Bollbach, Andrew Sesay, Ahmidu Barrie, Elizabeth Barrera, Kathryn Barron, John Welch, Nahid Bhadelia, Raphael G Frankfurter, Ophelia M Dahl, Sarthak Das, Rebecca E Rollins, Bryan Eustis, Amanda Schwartz, Piero Pertile, Ilias Pavlopoulos, Allan Mayfield, Regan H Marsh, Yusupha Dibba, Danielle Kloepper, Andrew Hall, Karin Huster, Michael Grady, Kimberly Spray, David A Walton, Fodei Daboh, Cora Nally, Sahr James, Gabriel S Warren, Joyce Chang, Michael Drasher, Gina Lamin, Sherry Bangura, Ann C Miller, Annie P Michaelis, Ryan McBain, M Jana Broadhurst, Megan Murray, Eugene T Richardson, Ted Philip, Gary L Gottlieb, Joia S Mukherjee, Paul E Farmer
An epidemic of Ebola virus disease (EVD) beginning in 2013 has claimed an estimated 11 310 lives in West Africa. As the EVD epidemic subsides, it is important for all who participated in the emergency Ebola response to reflect on strengths and weaknesses of the response. Such reflections should take into account perspectives not usually included in peer-reviewed publications and after-action reports, including those from the public sector, nongovernmental organizations (NGOs), survivors of Ebola, and Ebola-affected households and communities...
October 15, 2016: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/27650729/neurochemical-binding-profiles-of-novel-indole-and-benzofuran-mdma-analogues
#20
COMPARATIVE STUDY
Jakob A Shimshoni, Ilan Winkler, Ezekiel Golan, David Nutt
3,4-Methylenedioxy-N-methylamphetamine (MDMA) has been shown to be effective in the treatment of post-traumatic stress disorder (PTSD) in numerous clinical trials. In the present study, we have characterized the neurochemical binding profiles of three MDMA-benzofuran analogues (1-(benzofuran-5-yl)-propan-2-amine, 5-APB; 1-(benzofuran-6-yl)-N-methylpropan-2-amine, 6-MAPB; 1-(benzofuran-5-yl)-N-methylpropan-2-amine, 5-MAPB) and one MDMA-indole analogue (1-(1H-indol-5-yl)-2-methylamino-propan-1-ol, 5-IT). These compounds were screened as potential second-generation anti-PTSD drugs, against a battery of human and non-human receptors, transporters, and enzymes, and their potencies as 5-HT2 receptor agonist and monoamine uptake inhibitors determined...
January 2017: Naunyn-Schmiedeberg's Archives of Pharmacology
keyword
keyword
87183
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"